DNA repair dysregulation from cancer driver to therapeutic target

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405 · see citing works

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · see citing works

Instability and decay of the primary structure of DNA

Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679 · see citing works

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · see citing works

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · see citing works

Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability

Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., Fishel, R. A., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,181 · see citing works

ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage

Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075 · see citing works

Cell-cycle checkpoints and cancer

Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836 · see citing works

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · see citing works

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works

Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer

WISEMAN, H., & HALLIWELL, B. (1996) · Biochemical Journal · doi:10.1042/bj3130017 · Cited by 2,345 · see citing works

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279 · see citing works

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009 · see citing works

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints

Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · see citing works

Poly(ADP-ribose): novel functions for an old molecule

Schreiber, V., Dantzer, F., Amé, J., & de MURCIA, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,917 · see citing works

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Olaussen, K. A., Dunant, A., Fouret, P. J., Brambilla, E. M., André, F., Haddad, V., Clermont, E., Filipits, M., Pirker, R., Popper, H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,725 · see citing works

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655 · see citing works

γH2AX and cancer

Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623 · see citing works

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells

Dolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446 · see citing works

Regulation of DNA double-strand break repair pathway choice

Shrivastav, M., De Haro, L. P., & Nickoloff, J. A. (2008) · Cell Research · doi:10.1038/cr.2007.111 · Cited by 1,329 · see citing works

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311 · see citing works

PARP inhibition: PARP1 and beyond

Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298 · see citing works

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia.

Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253 · see citing works

Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors

Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · see citing works

Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM

Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220 · see citing works

G1 cell-cycle control and cancer

Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,217 · see citing works

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

Gelmon, K. A., Tischkowitz, M. D., MacKay, H. J., Swenerton, K. D., Robidoux, A., Tonkin, K. S., Hirte, H. W., Huntsman, D. D., Clemons, M. J., Gilks, C. B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117 · see citing works

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086 · see citing works

Untitled work

(1999) · PubMed · Cited by 1,030 · see citing works

DNA interstrand crosslink repair and cancer

Deans, A. J., & West, S. C. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3088 · Cited by 1,019 · see citing works

ATM and DNA-PK Function Redundantly to Phosphorylate H2AX after Exposure to Ionizing Radiation

Stiff, T., O’Driscoll, M., Rief, N., Iwabuchi, K., Löbrich, M., & Jeggo, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3207 · Cited by 1,010 · see citing works

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Fong, P. C. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui‐Roelvink, M., Gourley, C., Grève, J. D., Lubiński, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,009 · see citing works

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural &amp; Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001 · see citing works

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 859 · see citing works

Circulating tumour cells in cancer patients: challenges and perspectives

Pantel, K., & Alix‐Panabières, C. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.001 · Cited by 821 · see citing works

Integrating Genetic Approaches into the Discovery of Anticancer Drugs

Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W., & Friend, S. H. (1997) · Science · doi:10.1126/science.278.5340.1064 · Cited by 777 · see citing works

Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Brose, M., Rebbeck, T., Calzone, K., Stopfer, J., Nathanson, K., & Weber, B. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.18.1365 · Cited by 772 · see citing works

Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents.

Pegg, A. E. (1990) · PubMed · Cited by 734 · see citing works

Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining

Mahaney, B. L., Meek, K., & Lees‐Miller, S. P. (2009) · Biochemical Journal · doi:10.1042/bj20080413 · Cited by 723 · see citing works

Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer

Vilenchik, M. M., & Knudson, A. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135498100 · Cited by 717 · see citing works

Purified human BRCA2 stimulates RAD51-mediated recombination

Jensen, R. B., Carreira, A., & Kowalczykowski, S. C. (2010) · Nature · doi:10.1038/nature09399 · Cited by 715 · see citing works

A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage

El‐Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 660 · see citing works

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633 · see citing works

Association of BRCA1 with the hRad50-hMre11-p95 Complex and the DNA Damage Response

Zhong, Q., Chen, C.-F., Li, S., Chen, Y., Wang, C.-C., Xiao, J., Chen, P.-L., Sharp, Z. D., & Lee, W.-H. (1999) · Science · doi:10.1126/science.285.5428.747 · Cited by 626 · see citing works

DNA polymerases and cancer

Lange, S. S., Takata, K.-I., & Wood, R. D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2998 · Cited by 615 · see citing works

PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites

Haince, J.-F., McDonald, D., Rodrigue, A., Déry, U., Masson, J., Hendzel, M. J., & Poirier, G. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706734200 · Cited by 609 · see citing works

Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential

Tricker, A. R., & Preußmann, R. (1991) · Mutation Research/Genetic Toxicology · doi:10.1016/0165-1218(91)90123-4 · Cited by 557 · see citing works

ATM and Artemis promote homologous recombination of radiation‐induced DNA double‐strand breaks in G2

Beucher, A., Birraux, J., Tchouandong, L., Barton, O., Shibata, A., Conrad, S., Goodarzi, A. A., Krempler, A., Jeggo, P. A., & Löbrich, M. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.276 · Cited by 548 · see citing works

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 543 · see citing works

Cancer Risks and Mortality in Heterozygous ATM Mutation Carriers

Thompson, D. J., Duedal, S., Kirner, J., McGuffog, L., Last, J. I. K., Reiman, A., Byrd, P. J., Taylor, A. M. R., & Easton, D. F. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji141 · Cited by 543 · see citing works

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540 · see citing works

Overexpression of a kinase‐inactive ATR protein causes sensitivity to DNA‐damaging agents and defects in cell cycle checkpoints

Cliby, W. A., Roberts, C. J., Cimprich, K. A., Stringer, C. M., Lamb, J. R., Schreiber, S. L., & Friend, S. H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.1.159 · Cited by 534 · see citing works

Cancer incidence in persons with Fanconi anemia

Rosenberg, P. S., Greene, M. H., & Alter, B. P. (2003) · Blood · doi:10.1182/blood-2002-05-1498 · Cited by 514 · see citing works

The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art

Vos, M. D., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 491 · see citing works

Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487 · see citing works

Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter

Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E. (2000) · PubMed · doi:10.25405/ncl.34284429 · Cited by 486 · see citing works

Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N. J., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 480 · see citing works

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural &amp; Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465 · see citing works

Mechanisms of carcinogenesis induced by alkylating agents

Saffhill, R., Margison, G. P., & O'Connor, P. J. (1985) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(85)90009-5 · Cited by 458 · see citing works

Secondary BRCA1 Mutations in BRCA1 -Mutated Ovarian Carcinomas with Platinum Resistance

Swisher, E. M., Sakai, W., Karlan, B. Y., Wurz, K., Urban, N. D., & Taniguchi, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0088 · Cited by 457 · see citing works

Preclinical Evaluation of a Potent Novel DNA-Dependent Protein Kinase Inhibitor NU7441

Zhao, Y., Thomas, H. D., Batey, M. A., Cowell, I. G., Richardson, C. J., Griffin, R. J., Calvert, H., Newell, D. R., Smith, G. C. M., & Curtin, N. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4275 · Cited by 447 · see citing works

A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification

Almeida, K. H., & Sobol, R. W. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.01.009 · Cited by 437 · see citing works

A forward chemical genetic screen reveals an inhibitor of the Mre11–Rad50–Nbs1 complex

Dupré, A., Boyer-Châtenet, L., Sattler, R. M., Modi, A. P., Lee, J., Nicolette, M. L., Kopelovich, L., Jasin, M., Baer, R. J., Paull, T. T., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.63 · Cited by 416 · see citing works

Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer

Brenner, J. C., Ateeq, B., Li, Y., Yocum, A. K., Cao, Q., Asangani, I. A., Patel, S., Wang, X., Liang, H., Yu, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.010 · Cited by 414 · see citing works

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Zabludoff, S., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S. A., Haye, H. R., Horn, C. L., Janetka, J. W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0492 · Cited by 411 · see citing works

DNA topoisomerase II, genotoxicity, and cancer

McClendon, A. K., & Osheroff, N. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2007.06.009 · Cited by 407 · see citing works

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

Plummer, R., Jones, C., Middleton, M. R., Wilson, R. H., Evans, J., Olsen, A. L., Curtin, N. J., Boddy, A. V., McHugh, P. J., Newell, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 386 · see citing works

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

Golding, S. E., Rosenberg, E., Valerie, N. C. K., Hussaini, I. M., Frigerio, M., Cockcroft, X. F., Chong, W. Y., Hummersone, M., Rigoreau, L. J. M., Menear, K. A., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0519 · Cited by 385 · see citing works

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition

Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H. M., Odijk, H., Zelensky, A. N., Chris van, B. R. E. E., Stalpers, L. J. A., Buist, M. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101053108 · Cited by 353 · see citing works

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Byrski, T., Huzarski, T., Dent, R. A., Gronwald, J., Zuziak, D., Cybulski, C., Kładny, J., Górski, B., Lubiński, J., & Narod, S. A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 339 · see citing works

Spontaneous Homologous Recombination Is Induced by Collapsed Replication Forks That Are Caused by Endogenous DNA Single-Strand Breaks

Saleh-Gohari, N., Bryant, H. E., Schultz, N., Parker, K. M., Cassel, T. N., & Helleday, T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7158-7169.2005 · Cited by 334 · see citing works

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 326 · see citing works

Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells

Rass, E., Grabarz, A., Plo, I., Gautier, J., Bertrand, P., & López, B. S. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1641 · Cited by 325 · see citing works

DNA damage tolerance, mismatch repair and genome instability

Karran, P., & Bignami, M. (1994) · BioEssays · doi:10.1002/bies.950161110 · Cited by 310 · see citing works

Oxygen as a friend and enemy: How to combat the mutational potential of 8-oxo-guanine

van Loon, B., Markkanen, E., & Hübscher, U. (2010) · DNA repair · doi:10.1016/j.dnarep.2010.03.004 · Cited by 310 · see citing works

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Thomas, H. D., Calabrese, C. R., Batey, M. A., Canan, S. S., Hostomský, Z., Kyle, S., Maegley, K. A., Newell, D. R., Skalitzky, D. J., Wang, L.-Z., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0552 · Cited by 309 · see citing works

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

Weston, V., Oldreive, C., Skowrońska, A., Oscier, D. G., Pratt, G., Dyer, M. J. S., Smith, G. C. M., Powell, J. E., Rudzki, Z., Kearns, P. R., et al. (2010) · Blood · doi:10.1182/blood-2010-01-265769 · Cited by 300 · see citing works

Requirement for the Kinase Activity of Human DNA-Dependent Protein Kinase Catalytic Subunit in DNA Strand Break Rejoining

Kurimasa, A., Kumano, S., Boubnov, N. V., Story, M. D., Tung, C., Peterson, S., & Chen, D. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3877 · Cited by 298 · see citing works

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

Jaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., Yarosh, D. B., Bearman, S., Giroux, D. J., & Schold, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3310 · Cited by 297 · see citing works

Preventing Nonhomologous End Joining Suppresses DNA Repair Defects of Fanconi Anemia

Adamo, A., Collis, S. J., Adelman, C. A., Silva, N., Hořejšı́, Z., Ward, J. D., Martínez-Pérez, E., Boulton, S. J., & Volpe, A. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.026 · Cited by 297 · see citing works

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

Johnson, N., Li, Y., Walton, Z. E., Cheng, K. A., Li, D., Rodig, S. J., Moreau, L. A., Unitt, C., Bronson, R. T., Thomas, H. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2377 · Cited by 290 · see citing works

ATR inhibition selectively sensitizes G ₁ checkpoint-deficient cells to lethal premature chromatin condensation

Nghiem, P., Park, P. K., Kim, Y.-S., Vaziri, C., & Schreiber, S. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161281798 · Cited by 290 · see citing works

ATR: a master conductor of cellular responses to DNA replication stress

Flynn, R. L., & Zou, L. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.005 · Cited by 290 · see citing works

CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?

Antoni, L., Sodha, N., Collins, I., & Garrett, M. D. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2251 · Cited by 287 · see citing works

PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma

Brenner, J. C., Feng, F. Y.-C., Han, S., Patel, S., Goyal, S. V., Bou‐Maroun, L. M., Liu, M., Lonigro, R. J., Prensner, J. R., Tomlins, S. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3648 · Cited by 286 · see citing works

Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers

Jazaeri, A. A., Yee, C. J., Sotiriou, C. P., Brantley, K., Boyd, J. A., & Liu, E. T. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.13.990 · Cited by 282 · see citing works

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

Rajeshkumar, N. V., Oliveira, E. D., Ottenhof, N. A., Watters, J., Brooks, D. G., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274 · see citing works

A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia

Willmore, E., de Caux, S., Sunter, N. J., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2527 · Cited by 273 · see citing works

Transient Inhibition of ATM Kinase Is Sufficient to Enhance Cellular Sensitivity to Ionizing Radiation

Rainey, M. D., Charlton, M. E., Stanton, R. V., & Kastan, M. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0763 · Cited by 267 · see citing works

Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

Mukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomský, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 266 · see citing works

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

Drew, Y., Mulligan, E. A., Vong, W., Thomas, H. D., Kahn, S., Kyle, S., Mukhopadhyay, A., Los, G., Hostomský, Z., Plummer, E. R., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq509 · Cited by 262 · see citing works

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1227 · Cited by 259 · see citing works

Multiple roles of ATM in monitoring and maintaining DNA integrity

Derheimer, F. A., & Kastan, M. B. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.031 · Cited by 256 · see citing works

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

Redon, C. E., Nakamura, A., Zhang, Y., Ji, J. J., Bonner, W. M., Kinders, R. J., Parchment, R. E., Doroshow, J. H., & Pommier, Y. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0523 · Cited by 254 · see citing works

Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks

Digweed, M., & Sperling, K. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.004 · Cited by 250 · see citing works

Human AP endonuclease 1 (APE1): From mechanistic insights to druggable target in cancer

Abbotts, R., & Madhusudan, S. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.006 · Cited by 250 · see citing works

Targeted Modulation of MGMT: Clinical Implications

Liu, L., & Gerson, S. L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2543 · Cited by 245 · see citing works

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment

Chan, N. H. L., Pires, I. M., Bencokova, Z., Coackley, C. L., Luoto, K. R., Bhogal, N., Lakshman, M., Gottipati, P., Oliver, F. J., Helleday, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2352 · Cited by 243 · see citing works

Isolation of a small molecule inhibitor of DNA base excision repair

Madhusudan, S., Smart, F., Shrimpton, P. J., Parsons, J. L., Gardiner, L., Houlbrook, S., Talbot, D. C., Hammonds, T. R., Freemont, P. S., Sternberg, M. J. E., et al. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki781 · Cited by 239 · see citing works

Identification of Specific Inhibitors of Human RAD51 Recombinase Using High-Throughput Screening

Huang, F., Motlekar, N. A., Burgwin, C. M., Napper, A. D., Diamond, S. L., & Mazin, A. V. (2011) · ACS Chemical Biology · doi:10.1021/cb100428c · Cited by 232 · see citing works

Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival

Marsit, C. J., Liu, M., Nelson, H. H., Posner, M. R., Suzuki, M., & Kelsey, K. T. (2003) · Oncogene · doi:10.1038/sj.onc.1207256 · Cited by 228 · see citing works

Targeting DNA-PKcs and ATM with miR-101 Sensitizes Tumors to Radiation

Yan, D., Ng, W. L., Zhang, X., Wang, P., Zhang, Z., Mo, Y., Mao, H., Hao, C., Olson, J. J., Curran, W. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011397 · Cited by 227 · see citing works

Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

Gilad, O., Nabet, B. Y., Ragland, R. L., Schoppy, D. W., Smith, K. D., Durham, A. C., & Brown, E. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2286 · Cited by 225 · see citing works

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

Blasina, A., Hallin, J. F., Chen, E., Arango, M. E., Kraynov, E. A., Register, J., Grant, S. K., Ninkovic, S., Chen, P., Nichols, T., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2391 · Cited by 220 · see citing works

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

Friedman, H. S., Kokkinakis, D. M., Pluda, J. M., Friedman, A. H., Cokgor, I., Haglund, M. M., Ashley, D. M., Rich, J. N., Dolan, M. E., Pegg, A. E., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3570 · Cited by 213 · see citing works

Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

Patel, A. G., Lorenzo, S. B. D., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2890 · Cited by 212 · see citing works

Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.

Rosenzweig, K., Youmell, M. B., Palayoor, S. T., et al. (1997) · PubMed · Cited by 210 · see citing works

Anticancer therapy with checkpoint inhibitors: what, where and when?

Garrett, M. D., & Collins, I. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.014 · Cited by 204 · see citing works

DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1

Martin, S. A., McCabe, N., Mullarkey, M. J., Cummins, R., Burgess, D. J., Nakabeppu, Y., Oka, S., Kay, E. W., Lord, C. J., & Ashworth, A. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.046 · Cited by 201 · see citing works

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Kummar, S., Ji, J. J., Morgan, R. J., Lenz, H.-J., Puhalla, S. L., Belani, C. P., Gandara, D. R., Allen, D. E., Kiesel, B. F., Beumer, J. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2821 · Cited by 200 · see citing works

Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions

Plo, I. (2003) · DNA repair · doi:10.1016/s1568-7864(03)00116-2 · Cited by 198 · see citing works

Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines

Peasland, A., Wang, L.-Z., Rowling, E. J., Kyle, S., Chen, T., Hopkins, A. P., Cliby, W. A., Sarkaria, J. N., Beale, G., Edmondson, R. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.243 · Cited by 197 · see citing works

ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors

Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O'Connor, M. J., Bebb, D. G., & Lees-Miller, S. P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0872 · Cited by 193 · see citing works

Human MRE11 is inactivated in mismatch repair‐deficient cancers

Giannini, G., Ristori, E., Cerignoli, F., Rinaldi, C., Zani, M., Viel, A., Ottini, L., Crescenzi, M., Martinotti, S., Bignami, M., et al. (2002) · EMBO Reports · doi:10.1093/embo-reports/kvf044 · Cited by 187 · see citing works

DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy

Tubbs, J. L., Pegg, A. E., & Tainer, J. A. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.03.011 · Cited by 175 · see citing works

Fanconi anemia pathway–deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated

Kennedy, R. D., Chen, C. C., Stuckert, P., Archila, E. M., la Vega, M. A. D., Moreau, L. A., Shimamura, A., & D’Andrea, A. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31245 · Cited by 174 · see citing works

Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach

Hardcastle, I. R., Cockcroft, X. F., Curtin, N. J., Murr, M. D., Leahy, J. J. J., Stockley, M. L., Golding, B. T., Rigoreau, L. J. M., Richardson, C. J., Smith, G. C. M., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050444b · Cited by 173 · see citing works

Rational Design of Human DNA Ligase Inhibitors that Target Cellular DNA Replication and Repair

Chen, X., Zhong, S., Zhu, X., Dziegielewska, B., Ellenberger, T., Wilson, G. M., MacKerell, A. D., & Tomkinson, A. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6636 · Cited by 170 · see citing works

Polymorphisms in DNA Base Excision Repair Genes ADPRT and XRCC1 and Risk of Lung Cancer

Zhang, X., Miao, X., Liang, G., Hao, B., Wang, Y., Tan, W., Li, Y., Guo, Y., He, F., Wei, Q., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.722.65.3 · Cited by 170 · see citing works

Targeting the S and G2 checkpoint to treat cancer

Chen, T., Stephens, P., Middleton, F. K., & Curtin, N. J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.009 · Cited by 168 · see citing works

Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

Zhang, Y., Regairaz, M., Seiler, J. A., Agama, K., Doroshow, J. H., & Pommier, Y. G. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1304 · Cited by 164 · see citing works

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression

Usanova, S., Piée‐Staffa, A., Sied, U., Thomale, J., Schneider, A., Kaina, B., & Köberle, B. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-248 · Cited by 164 · see citing works

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

Samol, J., Ranson, M., Scott, E. N., Macpherson, E., Carmichael, J., Thomas, A., & Cassidy, J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9682-9 · Cited by 159 · see citing works

MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers

Vilar, E., Bartnik, C. M., Stenzel, S. L., Raskin, L., Ahn, J., Moreno, V. R., Mukherjee, B., Iniesta, M. D., Morgan, M. A., Rennert, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1120 · Cited by 148 · see citing works

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064

Bowman, K. J., White, A. W., Golding, B. T., Griffin, R., & Curtin, N. J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.670 · Cited by 143 · see citing works

Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Ranson, M., Middleton, M., Bridgewater, J., Lee, S., Dawson, M., Jowle, D., Halbert, G., Waller, S., McGrath, H., Gumbrell, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2198 · Cited by 135 · see citing works

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells

Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., & McArthur, G. A. (2012) · Oncogene · doi:10.1038/onc.2011.358 · Cited by 133 · see citing works

Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

Matthews, D. J., Yakes, M., Chen, J., Tadano, M., Bornheim, L. M., Clary, D. O., Tai, A., Wagner, J. M., Miller, N., Kim, Y. D., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3699 · Cited by 132 · see citing works

DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target

Jalal, S. I., Earley, J. N., & Turchi, J. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0761 · Cited by 130 · see citing works

ATR Affecting Cell Radiosensitivity Is Dependent on Homologous Recombination Repair but Independent of Nonhomologous End Joining

Wang, H., Wang, H., Powell, S. N., Iliakis, G., & Wang, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1289 · Cited by 130 · see citing works

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

Munck, J. M., Batey, M. A., Zhao, Y., Jenkins, H., Richardson, C. J., Cano, C., Tavecchio, M., Barbeau, J., Bárdos, J. I., Cornell, L., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0535 · Cited by 128 · see citing works

Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone.

Luo, M., & Kelley, M. R. (2004) · PubMed · Cited by 128 · see citing works

Epigenetic Inactivation of the Chromosomal Stability Control Genes BRCA1, BRCA2, and XRCC5 in Non–Small Cell Lung Cancer

Lee, M.-N., Tseng, R., Hsu, H., Chen, J.-Y., Tzao, C., Ho, W. L., & Wang, Y. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2694 · Cited by 124 · see citing works

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

Khan, O., Gore, M. E., Lorigan, P. C., Stone, J., Greystoke, A., Burke, W., Carmichael, J., Watson, A. J., McGown, G., Thorncroft, M. R., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.8 · Cited by 123 · see citing works

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells

Kreahling, J. M., Gemmer, J. Y., Reed, D. R., Letson, D. G., Bui, M. M., & Altiok, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0529 · Cited by 121 · see citing works

DNA Methylation in Ovarian Cancer

Ahluwalia, A., Hurteau, J. A., Bigsby, R. M., & Nephew, K. P. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6284 · Cited by 118 · see citing works

DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours

Bártková, J., Hořejšı́, Z., Sehested, M., Nesland, J. M., Meyts, E. R., Skakkebæk, N. E., Stucki, M., Jackson, S. P., Lukáš, J., & Bártek, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210553 · Cited by 117 · see citing works

Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells

Taverna, P., Liu, L., Hwang, H.-S., Hanson, A. J., Kinsella, T. J., & Gerson, S. L. (2001) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(01)00076-3 · Cited by 116 · see citing works

CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors

Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T., & D’Andrea, A. D. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-24 · Cited by 115 · see citing works

Targeting homologous recombination repair defects in cancer

Evers, B., Helleday, T., & Jonkers, J. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.06.001 · Cited by 113 · see citing works

Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies

Willers, H., Taghian, A. G., Luo, C., Treszezamsky, A. D., Sgroi, D. C., & Powell, S. N. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0149 · Cited by 110 · see citing works

The xeroderma pigmentosum pathway: Decision tree analysis of DNA quality

Naegeli, H., & Sugasawa, K. (2011) · DNA repair · doi:10.1016/j.dnarep.2011.04.019 · Cited by 109 · see citing works

Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks

Takemura, H., Rao, V. A., Sordet, O., Furuta, T., Miao, Z., Meng, L., Zhang, H., & Pommier, Y. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603747200 · Cited by 107 · see citing works

Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility

Heikkinen, K., Karppinen, S., Soini, Y., Mäkinen, M., & Winqvist, R. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.12.e131 · Cited by 107 · see citing works

A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.

Berman, D. B., Costalas, J. W., Schultz, D., et al. (1996) · PubMed · Cited by 106 · see citing works

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity

Choudhury, A., Zhao, H. W., Jalali, F., Rashid, S. A., Ran, J., Supiot, S., Kiltie, A. E., & Bristow, R. G. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0959 · Cited by 106 · see citing works

Ataxia-Telangiectasia-Mutated ( ATM ) Gene in Head and Neck Squamous Cell Carcinoma

Ai, L., Vo, Q. N., Zuo, C., Li, L., Ling, W., Suen, J. Y., Hanna, E. Y., Brown, K. D., & Fan, C. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-082-3 · Cited by 104 · see citing works

Induction of ATM Activation, Histone H2AX Phosphorylation and Apoptosis by Etoposide: Relation to Cell Cycle Phase

Tanaka, T., Halicka, H. D., Traganos, F., Seiter, K. P., & Darżynkiewicz, Z. (2007) · Cell Cycle · doi:10.4161/cc.6.3.3835 · Cited by 102 · see citing works

First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)

Plummer, R., Lorigan, P. C., Evans, J., Steven, N. M., Middleton, M. R., Wilson, R., Snow, K., Dewji, R., & Calvert, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.8013 · Cited by 98 · see citing works

A Dominant-Negative Form of the Major Human Abasic Endonuclease Enhances Cellular Sensitivity to Laboratory and Clinical DNA-Damaging Agents

McNeill, D. R., & Wilson, D. M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0329 · Cited by 97 · see citing works

Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]

Jobson, A. G., Lountos, G. T., Lorenzi, P. L., Llamas, J., Connelly, J., Cerna, D., Tropea, J. E., Onda, A., Zoppoli, G. M., Kondapaka, S. B., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154997 · Cited by 95 · see citing works

Synthetic lethal targeting of DNA double‐strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors

Sultana, R., McNeill, D. R., Abbotts, R., Mohammed, M. Z., Zdzienicka, M. Z., Qutob, H. M. H., Seedhouse, C., Laughton, C. A., Fischer, P. M., Patel, P. M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27512 · Cited by 93 · see citing works

DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy

Moeller, B. J., Yordy, J. S., Williams, M. D., Giri, U. P., Raju, U., Molkentine, D. P., Byers, L. A., Heymach, J. V., Story, M. D., Lee, J. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2641 · Cited by 92 · see citing works

Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy.

Rabik, C., Njoku, M., & Dolan, M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.03.004 · Cited by 92 · see citing works

Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes

Gaymes, T. J., Shall, S., MacPherson, L. J., Twine, N. A., Lea, N. C., Farzaneh, F., & Mufti, G. J. (2009) · Haematologica · doi:10.3324/haematol.2008.001933 · Cited by 83 · see citing works

SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization

Ismail, I. H., Mårtensson, S., Moshinsky, D. J., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1207303 · Cited by 81 · see citing works

Chk1, but not Chk2 , is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53

Carrassa, L., Broggini, M., Erba, E., et al. (2004) · Cell Cycle · doi:10.4161/cc.3.9.1080 · Cited by 80 · see citing works

Is Base Excision Repair a Tumor Suppressor Mechanism?

Sweasy, J. B., Lang, T., & DiMaio, D. (2006) · Cell Cycle · doi:10.4161/cc.5.3.2414 · Cited by 77 · see citing works

Defects in homologous recombination repair in mismatch-repair-deficient tumour cell lines

Mohindra, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.18.2189 · Cited by 76 · see citing works

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

Zaremba, T., Ketzer, P., Cole, M. F., Coulthard, S. A., Plummer, E. R., & Curtin, N. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605166 · Cited by 73 · see citing works

Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers

Zaremba, T., Thomas, H. D., Cole, M. F., Coulthard, S. A., Plummer, E. R., & Curtin, N. J. (2011) · Biochemical Journal · doi:10.1042/bj20101723 · Cited by 72 · see citing works

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines

Mohammed, M., Vyjayanti, V. N., Laughton, C. A., Dekker, L. V., Fischer, P. M., Wilson, D. M., Abbotts, R., Shah, S., Patel, P. M., Hickson, I. D., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606058 · Cited by 71 · see citing works

Polymorphisms ofLIG4andXRCC4involved in the NHEJ pathway interact to modify risk of glioma

Liu, Y., Zhou, K., Zhang, H., Shugart, Y. Y., Chen, L., Xu, Z., Zhong, Y., Liu, H., Li, J., Wei, Q., et al. (2007) · Human Mutation · doi:10.1002/humu.20645 · Cited by 71 · see citing works

DNA-Dependent Protein Kinase Is a Molecular Target for the Development of Noncytotoxic Radiation–Sensitizing Drugs

Shinohara, E., Geng, L., Tan, J., Chen, H., Shir, Y., Edwards, E., Halbrook, J., Kesicki, E., Kashishian, A., & Hallahan, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4250 · Cited by 71 · see citing works

Polymorphisms in nonhomologous end‐joining genes associated with breast cancer risk and chromosomal radiosensitivity

Willems, P., Claes, K., Baeyens, A., Vandersickel, V., Werbrouck, J., Ruyck, K. D., Poppe, B. G., den Broecke, R. V., Makar, A. P., Marras, E., et al. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20515 · Cited by 67 · see citing works

Cloning of novel mammary tumor progression and metastasis genes

Kimm, M. A., Boer, M., Gaemers, I. C., & Hilkens, J. (2001) · Breast Cancer Research · doi:10.1186/bcr362 · Cited by 65 · see citing works

Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers

Vollebergh, M. A., Jonkers, J., & Linn, S. C. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0809-0 · Cited by 65 · see citing works

Inhibitors of DNA polymerase β: Activity and mechanism

Gao, Z., Maloney, D. J., Dedkova, L. M., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.02.071 · Cited by 64 · see citing works

Adhesion molecules and TGF-β1 are involved in the peritoneal dissemination of NUGC-4 human gastric cancer cells

Nakashio, T., Narita, T., Akiyama, S., Kasai, Y., Kondo, K., Ito, K., Takagi, H., & Kannagi, R. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970304)70:5 · Cited by 64 · see citing works

Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review

Lavecchia, A., Giovanni, C. D., & Novellino, E. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543771003623232 · Cited by 64 · see citing works

NBS1 Heterozygosity and Cancer Risk

di Masi, A., & Antoccia, A. (2008) · Current Genomics · doi:10.2174/138920208784533610 · Cited by 62 · see citing works

Imatinib sensitizes CLL lymphocytes to chlorambucil

Aloyz, R. S., Grzywacz, K., Xu, Z.-Y., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403247 · Cited by 61 · see citing works

Aberration of poly(adenosine diphosphate-ribose) metabolism in human colon adenomatous polyps and cancers.

Hirai, K., Ueda, K., & Hayaishi, O. (1983) · PubMed · Cited by 58 · see citing works

Heterozygous ATR Mutations in Mismatch Repair–Deficient Cancer Cells Have Functional Significance

Lewis, K. A., Mullany, S. A., Thomas, B., CHIEN, J. R., Loewen, R. T., Shridhar, V., & Cliby, W. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1019 · Cited by 58 · see citing works

A real-time fluorescence method for enzymatic characterization of specialized human DNA polymerases

Dorjsuren, D. G., Wilson, D. M., Beard, W. A., McDonald, J. P., Austin, C. P., Woodgate, R., Wilson, S. H., & Simeonov, A. M. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp641 · Cited by 57 · see citing works

IRC‐083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells

Brézak, M.-C., Valette, A., Quaranta, M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24080 · Cited by 55 · see citing works

Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab

Prewett, M. C., Deevi, D. S., Bassi, R., Fan, F., Ellis, L. M., Hicklin, D. J., & Tonra, J. R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1768 · Cited by 52 · see citing works

Quantitative immunohistochemical estimates of O6-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon.

Zaidi, N. H., Liu, L., & Gerson, S. L. (1996) · PubMed · Cited by 44 · see citing works

3-O-methylfunicone, a selective inhibitor of mammalian Y-family DNA polymerases from an Australian sea salt fungal strain

Mizushina, Y., Motoshima, H., Yamaguchi, Y., Takeuchi, T., Hirano, K., Sugawara, F., & Yoshida, H. (2009) · Marine Drugs · doi:10.3390/md7040624 · Cited by 42 · see citing works

Organ and cell specificity of base excision repair mutants in mice

Larsen, E., Meza, T. J., Kleppa, L., & Klungland, A. (2006) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.01.023 · Cited by 41 · see citing works

Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone

Rowe, J. D. D., Bello, J. A., Mitnick, R. J., et al. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00374-5 · Cited by 40 · see citing works

Frameshift Mutations at Coding Mononucleotide Repeats of the hRAD50 Gene in Gastrointestinal Carcinomas with Microsatellite Instability

Kim, N., Choi, Y. R., Baek, M. J., et al. (2001) · Cited by 40 · see citing works

Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin

Boulton, S. J., Kyle, S., & Durkacz, B. W. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00311-1 · Cited by 39 · see citing works

Poly(ADP-Ribose) Polymerase 1 Modulates the Lethality of CHK1 Inhibitors in Carcinoma Cells

Mitchell, C., Park, M., Eulitt, P. J., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067199 · Cited by 39 · see citing works

Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition

Höglund, A., Strömvall, K., Li, Y., Forshell, L. P., & Nilsson, J. A. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17887 · Cited by 39 · see citing works

Amino Acid Asp181 of 5′-Flap Endonuclease 1 Is a Useful Target for Chemotherapeutic Development

Panda, H., Jaiswal, A. S., Corsino, P. E., et al. (2009) · Biochemistry · doi:10.1021/bi9010754 · Cited by 36 · see citing works

An upstream ORF with non-AUG start codon is translated in vivo but dispensable for translational control of GCN4 mRNA

Zhang, F., & Hinnebusch, A. G. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1251 · Cited by 36 · see citing works

Cohesin: a regulator of genome integrity and gene expression

Feeney, K. M., Wasson, C. W., & Parish, J. L. (2010) · Biochemical Journal · doi:10.1042/bj20100151 · Cited by 35 · see citing works

Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition

Kuschal, C., Thoms, K., Boeckmann, L., Laspe, P., Apel, A., Schön, M. P., & Emmert, S. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01320.x · Cited by 34 · see citing works

Tumor O6-methylguanine-DNA Methyltransferase Inactivation by Oral Lomeguatrib

Watson, A. J., Sabharwal, A., Thorncroft, M. R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1389 · Cited by 34 · see citing works

Impairment of double‐strand breaks repair and aberrant splicing of ATM and MRE11 in leukemia–lymphoma cell lines with microsatellite instability

Ham, M. F., Takakuwa, T., Luo, W., Liu, A., Horii, A., & Aozasa, K. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00165.x · Cited by 31 · see citing works

Differential inhibitory effect of OK-1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks

Kruszewski, M. K., Wojewódzka, M., Iwaneñko, T., et al. (1998) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(98)00040-8 · Cited by 28 · see citing works

Nucleotide Excision Repair and its Connection with Cancer and Ageing

Andressoo, J., Hoeijmakers, J. H. J., & de Waard, H. (2006) · Springer eBooks · doi:10.1007/1-4020-3764-3_3 · Cited by 24 · see citing works

CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma

Benson, D. M., & Byrd, J. C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4061 · Cited by 22 · see citing works

DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs

Fordham, S. E., Matheson, E. C., Scott, K. E., Irving, J. A. E., & Allan, J. M. (2011) · Leukemia · doi:10.1038/leu.2011.38 · Cited by 20 · see citing works

Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases.

Mehta, M. P., Curran, W. J., Wang, D., Wang, F., Kleinberg, L. R., Brade, A. M., Mostafa, N. M., Zhou, X., Qian, J. X., Leahy, T., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2013 · Cited by 17 · see citing works

Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.

Schellens, J. H. M., Shapiro, G. I., Pavlick, A. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3068 · Cited by 15 · see citing works

Causal Link between Microsatellite Instability and hMRE11 Dysfunction in Human Cancers

Wu, X., Yang, X., Chai, W., & Her, C. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0322 · Cited by 11 · see citing works

Enhancement of human cancer cell radiosensitivity by conjugated eicosapentaenoic acid - a mammalian DNA polymerase inhibitor

Mizushina (2010) · International Journal of Oncology · doi:10.3892/ijo_00000532 · Cited by 10 · see citing works

Drug resistance in cancer: An overview

Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463 · see citing works

ROS and the DNA damage response in cancer

Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144 · see citing works

Mechanisms of DNA damage, repair, and mutagenesis

Chatterjee, N., & Walker, G. C. (2017) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22087 · Cited by 2,039 · see citing works

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · see citing works

Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives

Hajam, Y. A., Rani, R., Ganie, S. Y., Sheikh, T. A., Javaid, D., Qadri, S. S., Pramodh, S., Alsulimani, A., Alkhanani, M. F., Harakeh, S., et al. (2022) · Cells · doi:10.3390/cells11030552 · Cited by 915 · see citing works

Therapeutic opportunities within the DNA damage response

Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587 · see citing works

Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia

Zambetti, N. A., Ping, Z., Chen, S., Kenswil, K. J. G., Mylona, M. A., Sanders, M. A., Hoogenboezem, R. M., Bindels, E. M. J., Adisty, M. N., Van Strien, P. M. H., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.08.021 · Cited by 342 · see citing works

Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress

Yan, S., Sorrell, M., & Berman, Z. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1666-4 · Cited by 247 · see citing works

Trapping Poly(ADP-Ribose) Polymerase

Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230 · see citing works

Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients

Gruosso, T., Mieulet, V., Cardon, M., Bourachot, B., Kieffer, Y., Devun, F., Dubois, T., Dutreix, M., Vincent‐Salomon, A., Miller, K. M., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505891 · Cited by 179 · see citing works

The Good, the Bad, and the Ugly of ROS: New Insights on Aging and Aging‐Related Diseases from Eukaryotic and Prokaryotic Model Organisms

Santos, A. L., Sinha, S., & Lindner, A. B. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1941285 · Cited by 168 · see citing works

Mutational signature analysis identifies <i> <scp>MUTYH</scp> </i> deficiency in colorectal cancers and adrenocortical carcinomas

Pilati, C., Shinde, J., Alexandrov, L. B., Assié, G., André, T., Hélias‐Rodzewicz, Z., Ducoudray, R., Le Corre, D., Zucman‐Rossi, J., Emile, J., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4880 · Cited by 150 · see citing works

Microbiota impact on the epigenetic regulation of colorectal cancer

Yang, T., Owen, J. L., Lightfoot, Y. L., Kladde, M. P., & Mohamadzadeh, M. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.08.005 · Cited by 90 · see citing works

Targeting the Translesion Synthesis Pathway for the Development of Anti-Cancer Chemotherapeutics

Korzhnev, D. M., & Hadden, M. K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00596 · Cited by 58 · see citing works

Targeting DNA damage repair pathways in pancreas cancer

Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43 · see citing works

Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy

Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42 · see citing works

MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT Signaling

Han, Y., Peng, Y., Fu, Y., Cai, C., Guo, C., Liu, S., Li, Y., Chen, Y., Shen, E., Long, K., et al. (2020) · Advanced Science · doi:10.1002/advs.202000112 · Cited by 34 · see citing works

Computed cancer interactome explains the effects of somatic mutations in cancers

Zhang, J., Pei, J., Durham, J., Bos, T., & Cong, Q. (2022) · Protein Science · doi:10.1002/pro.4479 · Cited by 31 · see citing works

Drugging the Cancers Addicted to DNA Repair

Nickoloff, J. A., Jones, D. V., Lee, S., Williamson, E. A., & Hromas, R. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx059 · Cited by 159 · see citing works

DNA repair and synthetic lethality

Guo, G., Zhang, F., Gao, R., Delsite, R., Feng, Z., & Powell, S. N. (2011) · International Journal of Oral Science · doi:10.4248/ijos11064 · Cited by 40 · see citing works

Evolving DNA repair synthetic lethality targets in cancer

Kulkarni, S., Brownlie, J., Jeyapalan, J. N., Mongan, N. P., Rakha, E. A., & Madhusudan, S. (2022) · Bioscience Reports · doi:10.1042/bsr20221713 · Cited by 25 · see citing works

The role of progesterone-induced blocking factor (PIBF) in invasion of primary ovarian tumour cells

Balassa, T., Berta, G., Bohonyi, N., et al. (2017) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2017.07.027

Cellular Responses to DNA Damage

Klapacz, J., & Gollapudi, B. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95611-3 · Cited by 2 · see citing works